Pfizer

Pfizer Inc’s Ibrance Drug Proves It Can Slow down Progression of Breast Cancer

Pfizer Inc’s Ibrance Drug Proves It Can Slow down Progression of Breast Cancer

Pfizer Inc's Ibrance drug in a phase-III trial confirmed that when combined with hormone remedy, it can double the period of illness management for ladies with most typical sort of breast cancers.

News: 
Location: 
Company: 

Pfizer Faces Multiple Lipitor Lawsuits

Pfizer Faces Multiple Lipitor Lawsuits

American multinational pharmaceutical company Pfizer is under pressure after facing number of lawsuits related to the side effects of Lipitor.

Location: 
Company: 

Pfizer Experimental Drug Shows Promising Results in Phase II Study

Pfizer Experimental Drug Shows Promising Results in Phase II Study

Pharmaceutical major Pfizer has reported encouraging results in an early clinical trial for experimental advanced breast cancer drug. The Phase II study of drug palbociclib carried out on 165 patients in combination with other therapies has shown positive outcomes.

Dr. Dennis Slamon, a physician at UCLA said that the results are impressive and the success of current study would help Pfizer get approval from U.S. FDA. Dr Slamon has worked with Pfizer on the research and development project for palbociclib.

Location: 
Laboratories: 
Company: 

Pfizer Voluntarily Recalls 3 Lots of Effexor XR

Pfizer Voluntarily Recalls 3 Lots of Effexor XR

The U. S. Food and Drug Administration announced about Pfizer voluntarily recalling three lots of Effexor XR. The company has issued recall as the lots might have been contaminated with a heart drug and could lead to fatal consequences.

"Although Pfizer has not received any other such reports, these three lots are being voluntarily recalled as a precaution because they were packaged on the same line", said Pfizer.

Location: 
Company: 

Pfizer Prevnar 13 Shows Impressive Results in Post-approval Study

Pfizer Prevnar 13 Shows Impressive Results in Post-approval Study

Pfizer Inc has reported successful results for pneumonia drug Prevnar 13 in a large study conducted on 85,000 patients. The vaccine protects against Streptococcus pneumoniae bacteria infection in children and adults over 65 years of age.

The drug trial involving 85,000 patients, termed as CAPiTA, has shown impressive results for community-acquired pneumonia. More than 300,000 adults over 50 years of age are hospitalized for treatment of pneumococcal pneumonia every year. The company announced that Prevnar 13 has met the targets in post-approval study conducted in the Netherlands.

Company: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More

Tesla announces risky new approach to customer service

During the past few years, Tesla was slammed by a... Read More